Arboreal Bioinnovations, a Lucknow-based specialty food and nutraceutical ingredients company, has raised ₹230 crore (over $24 million) in a Series A round co-led by EAAA Alternatives, the alternatives investment arm of Edelweiss, and agrifood-focused Omnivore, with existing investor Rainmatter by Zerodha also participating.
The size of the round stands out in a segment that rarely sees Series A cheques this large. India’s specialty ingredients industry has quietly become one of the more capital-intensive corners of the food-tech ecosystem, as consumer packaged goods companies push suppliers to deliver science-backed alternatives — sugar-reduction systems, alternative proteins, cocoa-based ingredients — fast enough to keep pace with shifting nutrition labels and health-conscious demand. Building that kind of ingredient engineering and precision manufacturing capability upfront costs more than a typical software or D2C Series A, which is part of why investors are willing to write outsized early checks into companies that can prove out the science.
Founded in 2018 by Swati Pandey and Manish Chauhan, Arboreal runs an integrated platform spanning ingredient engineering, process R&D, formulation science and precision manufacturing, and says it has supported more than 300 product launches for over 1,100 B2B customers across food, beverage and nutraceutical categories. The Series A is also the first investment out of EAAA’s second Discovery Fund, which closed above ₹1,200 crore — meaning Arboreal effectively became the debut bet for a freshly capitalised pool of money specifically built to back category-defining businesses.
Also Read: Mitti Labs raises $9.5 Mn Series A led by Aramco Ventures
“This fundraise is a strong validation of the direction we are taking as a company. It gives us the fuel to accelerate our mission of building clean, science-led solutions that address some of the world’s most pressing nutritional and food challenges, with innovation originating in India and reaching consumers globally.” said Swati Pandey, Co-founder & CEO, Arboreal Bioinnovations
The company plans to direct the capital toward expanding manufacturing capacity, deepening R&D, and speeding up commercialisation of its next generation of functional ingredients. For a Discovery Fund built to find and back category leaders early, Arboreal’s ability to already claim 1,100 customers and 300 product launches likely mattered more than the ticket size — it suggests the science has cleared commercial validation, leaving capital as the remaining constraint on scale.
